SIGA Technologies, Inc.

NASDAQ:SIGA

Drug Manufacturers - Specialty & Generic

Healthcare
$2.80 -0.36%

-$0.02 today

Market cap
$201.19M
Beta
0.85
P/E (TTM)
15.2
EPS (TTM)
$0.28
Dividend yield
13.97%
52W Low $4.10High $9.62

Volume 0.37M

Average 0.61M

SIGA Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

SIGA Technologies, Inc.NASDAQ: SIGA

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $2.94M rose 1764.4% year over year, ahead of the +15.1% change in trailing-twelve-month cost of revenue. Sequentially, it fell 1.6% from the prior quarter. Over 3 fiscal years it compounded at +41.7% a year.

Context

  • Cost of revenue amounted to 31.4% of revenue in FY2025, up 8.8 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +1764.4% holds above the trailing-twelve-month pace of +15.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.94M-1.6% QoQ
Last fiscal yearDec 2025
$29.7M-5.1% YoY
LTMMar 2026
$32.49M+15.1% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1764.4%——
1 year-5.1%——
3-year CAGR+41.7%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
29.7M USD
Year-over-year change
-5.1%
4-year CAGR
+15.7%

Cost of Revenue vs competitors

How SIGA compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +15.1% is the 3rd highest of 8, against a peer median of +0.2%.
  • Cost of revenue amounts to 34.6% of revenue for SIGA, versus a peer median of 35.8%.
SIGA Competitors
Cost of Revenue for SIGA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNDLSNDL Inc.LTM Mar 2026CA$682.57M CAD+0.2%+6.3%72.8%
EBSEmergent BioSolutions Inc.LTM Mar 2026$376M USD-38.7%-15.3%55.6%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$151.94M USD+37.2%+9.4%29.6%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$146.39M USD+62.5%+68.6%35.0%
SIGASIGA Technologies, Inc.LTM Mar 2026$32.49M USD+15.1%+41.7%34.6%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$19.82M USD-5.8%+123.9%6.6%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$18.37M USD+7.2%-4.0%36.5%
DRIODarioHealth Corp.LTM Mar 2026$9.21M USD-2.6%-18.6%43.5%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$306K USD———
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$251K USD——0.7%
Peer median (excluding SIGA) —+0.2%+6.3%35.8%

Competitors are the stored peer set for SIGA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue133.67M110.78M139.92M138.72M94.6M
Cost of Revenue16.6M10.43M17.83M31.29M29.7M
Gross Profit117.07M100.34M122.09M107.43M64.87M
Gross Margin87.6%90.6%87.3%77.4%68.6%
Research & Development9.94M22.53M16.43M12.31M6.53M
Selling, General & Admin18.03M35.12M22.04M25.14M3.13M
Operating Expenses27.98M57.64M38.47M37.45M41.17M
Depreciation & Amortization522.37K517.64K538.29K538.42K562.61K
EBITDA89.83M44.65M88.31M76.61M30.96M
EBITDA Margin67.2%40.3%63.1%55.2%32.7%
Operating Income89.09M42.7M83.62M69.98M23.7M
Operating Margin66.7%38.5%59.8%50.4%25.1%
Interest Income00006.68M
Interest Expense00000
Other Income / Expenses218.94K1.43M4.16M6.09M6.7M
Income Before Tax89.31M44.13M87.78M76.07M30.4M
Pre-Tax Margin66.8%39.8%62.7%54.8%32.1%
Income Tax Expense19.86M10.23M19.71M16.86M7.1M
Net Income69.45M33.9M68.07M59.21M23.3M
Net Margin52.0%30.6%48.6%42.7%24.6%
EPS (Basic)0.920.460.950.830.33
EPS (Diluted)0.910.460.950.830.33
Weighted Avg Shares75.32M72.93M71.36M71.25M71.6M
Weighted Avg Shares (Diluted)76.4M73.55M71.68M71.77M71.6M

SIGA Technologies, Inc.

NASDAQ:SIGA

Intrinsic Alpha fair value

Locked

Current Price

$2.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.